Many human tumor ceils have been shown to express antigens that are recognized by autologous cytotoxic T lymphocytes (CTL) and the molecular nature era number of melanoma antigens has been defined recendy. Here we describe the characterization of an antigen recognized on a renal ceil carcinoma by autologous CTL clones. This antigen is encoded by the HLA-A2 gene present in the tumor cells. The sequence of this gene differs from the HLA-A2 sequence found in autologous peripheral blood lymphocytes by a point mutation that results in an arginine to isoleucine exchange at residue 170, which is located on the a-helix of the ct2 domain. Transfection experiments with the normal and mutated HLA-A2 cDNA demonstrated that this amino acid replacement was responsible for the recognition of the HLA-A2 molecule expressed on the tumor cells. The mutant HLA-A2 gene was also detected in the original tumor tissue from the patient, excluding the possibility that the mutation had appeared in vitro. Thus, HLA class I molecules carrying a tumor-specific mutation can be involved in the recognition of tumor cells by autologous CTL.
Summary
Many human tumor ceils have been shown to express antigens that are recognized by autologous cytotoxic T lymphocytes (CTL) and the molecular nature era number of melanoma antigens has been defined recendy. Here we describe the characterization of an antigen recognized on a renal ceil carcinoma by autologous CTL clones. This antigen is encoded by the HLA-A2 gene present in the tumor cells. The sequence of this gene differs from the HLA-A2 sequence found in autologous peripheral blood lymphocytes by a point mutation that results in an arginine to isoleucine exchange at residue 170, which is located on the a-helix of the ct2 domain. Transfection experiments with the normal and mutated HLA-A2 cDNA demonstrated that this amino acid replacement was responsible for the recognition of the HLA-A2 molecule expressed on the tumor cells. The mutant HLA-A2 gene was also detected in the original tumor tissue from the patient, excluding the possibility that the mutation had appeared in vitro. Thus, HLA class I molecules carrying a tumor-specific mutation can be involved in the recognition of tumor cells by autologous CTL.
I
n the last five years, knowledge of human tumor antigens .recognized by autologous CTL has 'increased considerably. So far, genetic and biochemical approaches have led to the molecuhr identification of three classes of antigens, The first class comprises antigens encoded by genes that are expressed in various tumors of different histological origins, but not in normal tissues other than testis, such as MAGE-1 (1, 2), MAGF.-3 (3), BAGE (4), and GAGE-l~2 (5) . The second class represents differentiation antigens encoded by genes that are only expressed irt melanoma and normal melanocytes, like tyrosinase (6), Melan-A MAr~T-t (7, g), glgI00 P'mt'll7 (9, 10) , and ~75 TRy) (11) . The third class includes antigens produced by unique point mutations in genes that are ubiquitously expressed, such a~ MUM. I (I2) and CDK4 (13) . In both cases, the antigenic peptide is encoded by the mutated region of the gene, Both renal cell carcinoma 0a.CC) ~ and melanoma are considcred potentially immunogcnic in humans, Both types of tumor are often infiltrated by T lymphocytes, and m 9 static lesions werr found to re~ress spontaneously in a small but significant number of ca~s (14) (15) (16) (17) (18) . Durable tumoral responses were observed afar IL-2 treatment in 15~20% of cases, and some of therrt may result from the elicitation of tAbbte~iations uged in thi~ paper: KCC, renal Cell c~rciho~a; g.ql', teVcrge Ifamcril~tOn.
T cell responses (19, 20) . This suggests that kidney tumors, like melanomas, express antigens that can be recognized by autologom T lymphocytes. However, our knowledge of tumor-specific antigens expressed on ILCC is scarce. In contrast to melanoma, it proved difficult to adapt RCC to in vitro culture conditions, and to generate stable CTL clones for the identification of antigens present on this type of tumor. In addition, genes MAGE-1, MAGE-3, BAGE, and GAGE-l~2 are expressed in various tumors but not in I~CC,
Here we report the identification of an antigen that is recognized by autologous CTL on human KCC cell line LB996~RCC. The antigen is encoded by a mutated HLA-A2 genr
Matedals and Methods
Cell Lines, I~CC cell line LB996-KCC was derived from the primary tumor of 6%yr-old Caucasian patient LB996 (HLA-A2, -A11, -B18, -B44, -CwI, and -.Cw*1601) and grown as previously described (21) . This patient died of pulmonary embolism 7 wk after ngphrectomy for a stage II1 KCC that invaded the inferior verla eava, Lymphoblastoid cell line LB996-EDV was derived from the PDL oa e lratient LB996 by standard techniques, GTL glone 314/4 w;t~ det'ived from LD996~PBL which were ,tirrtulatod in vitro with itr~glia~d atatologous LB996-P, CC gellL This CTL clone expre~ed both CD4 and CD8 molecules. Other CTL clones obtained similarly expressed only CD8 and were also directed against HLA-A*0201-R170I (data not shown). RFLP analysis confirmed that LB996-ILCC and LB996-PBL originated from the same patient (data not shown). HeLa-S3 cells were obtained from the American Type Culture Collection (Rockville, MD). They were transfected by the calcium phosphate precipitate method with HLA-A*O201-R170I or HLA-A*0201 cDNA cloned individually into plasmid pcDNA3 (Invitrogen Corp., San Diego, CA) which contains the neomycin resistance gene. Clonal sublines were isolated from transfected populations resistant to G418 (2 mg/ml).
Cytotoxicity Assay. The lyric activity of CTL was tested in a chromium release assay as previously described (22) . Briefly, 1,000 chromium-labeled cells in 100 Ixl were incubated in 96-well microplates with an equal volume of CTL at different effectot to target ratios. Chromium release was measured after 4 h of incubation.
CTL Stimulation Assay. 2,500 CTL were added to microwells containing stimulator cells in 100 pA of lscove medium (GIBCO BRL, Gaithersburg, MD) supplemented with 10% human serum and 25 U/ml r-hu-IL-2. After 18 h, the supernatant was collected and its TNF content determined by testing the cytotoxic effect on WEHI-164 clone 13 cells (23) Construction of the eDNA Library. Total ILNA was extracted by the guanidine-isothiocyanate procedure (28) from LB996-RCC cells that had undergone 25 in vitro passages after surgical removal from patient LB996. Poly(-A) + ILNA enriched by an oligo(dT)-cellulose column was converted to cDNA with the Supersctipt Choice System (GIBCO BILL) using an ofigo(dT) primer containing a Notl site at its 5' end. The eDNA was ligated to BstXI adaptors, digested with Notl, and inserted into the BstXI and NotI sites of expression vector pcDNA3. Recombinant plasnfids were electroporated into Escherichia coli Topl0F' and selected with ampicillin (100 p~g/ml). The library was divided into 400 pools of 100 eDNA clones. Each pool of bacteria was amplified to saturation and plasmid DNA was extracted using the QIAprep 8 plasmid kit (Qiagen GmbH, Hilden, Germany).
Transfection of COS-7 Cells for Screening the cDNA Library.
Transient transfection was performed by the DEAE-dextranchloroquine method (29) . Briefly, 1.5 • 104 COS-7 cells were transfected with 100 ng of plasmid DNA from a pool from the eDNA library, and 100 ng of plasmid pcDNA3 containing the HLA-A*0201 gene that was derived from an unrelated individual (30) . Transfected COS-7 cells were tested in a CTL stimulation assay after 48 h.
Cloning of the HLA-A2 cDNA fiom LB996-PBL. Total RNA was extracted from LB996-PBL by the guanidine-isothiocyanate procedure (28) . Reverse transcription (ILT) was performed on 2 p,g of total RNA in a 20-I.tl reaction volume containing 4 I.tl of 5• reverse transcriptase buffer (GIBCO BRL), 1 I-tl each of 10 mM dNTP, 2 ILl ofa 20-~zM solution of oligo(dT)15 primer, 20 U of ILNasin (Promega Corp., Madison, WI), 2 ILl of 0.1 M dithiothreitol, and 200 U of Moloney murine leukemia virus reverse transcriptase (GIBCO BILL). The reaction was incubated at 42~ for 60 rain. One-twentieth of the cDNA product was then supplemented with 10 I-tl of 10• polymerase buffer, 2 ~1 each of 10 mM dNTP, 5 ~zl each of 20 p.M primer solutions, 2.5 U of PFU DNA polymerase (Stratagene Inc., La Jolla, CA) and water to a final volume of 100 Ixl. PCR amplification was carried out using forward primer 5'-GGCGAATTCGGACTCAGAATCTCCCC-AGACGCCGAG and reverse primer 5'-CCCGAATTCTCT-CAGTCCCTCACAAGGCAGCTGTC that hybridize to the 5' and 3' untranslated regions of all HLA class I genes respectively, and that both contain an EcoRI site (31) . An initial denaturation step was performed for 4 rain at 94~ followed by 30 cycles (1 rain at 94~ 5 s at 62~ and 3 rain at 75~ and 5 additional cycles (1 n-fin at 94~ 5 s at 62~ and 5 rain at 75~
The amplification finished with 10 min at 75~ The PCIL product was digested with EcoRI and inserted into the EcoRl site ofpcDNA3.
DNA Sequence Analysis. DNA sequencing was performed by the dideoxy-chain termination method (T7 Sequencing Kit; Pharmacia, Uppsala, Sweden) using specific oligonucleotides as primers. The computer search for sequence homology was performed with the blast@ncbi.nlm.nih.gov, program, (National Library of Medicine, NIH, Bethesda, MD). 
PCR Amplification of HLA-

Results
CTL Clones Specific for RCC Cell Line LB996oRCC.
By stimulating PBL from patient LB996 with irradiated cells from autologous RCC line LB996-RCC, we isolated a panel of CTL clones that specifically lysed the tumor cells, but not an autologous EBV-transformed B cell line or NK cell target K562. Results obtained with representative CTL clone 314/4 are shown (Fig. 1 A) .
CTL clone 314/4 produced TNF when stimulated with LB996-RCC cells, and this TNF production was blocked by a mAb that binds to all HLA class I molecules (Fig. 1 B) . Partial inhibition of TNF production was also observed in the presence of mAbs directed against HLA-A2 or against CD8, suggesting that the target antigen is presented by HLA-A2.
Identification of a cDNA Coding for the Antigen Recognized by CTL314/4.
To clone the gene conferring recognition by CTL 314/4, we prepared a cDNA library from RNA of LB996-RCC cells in expression vector pcDNA3. We divided the library into 400 pools of 100 bacteria and transfected duphcate microcultures of COS-7 cells with DNA from each pool together with a plasmid coding for HLA-A*0201. We tested the transfected cells 48 h later for their ability to induce TNF release by CTL 314/4. Three cDNA pools proved positive. By subcloning one of them, we isolated three cDNA clones that transferred the expression of the antigen recognized by CTL 314/4. The result of representative cDNA clone 3B10 is shown (Fig. 2) . Surprisingly, the expression of HLA-A*0201 was not necessary as COS-7 cells transfected with clone 3B10 alone were able to stimulate TNF production.
A Mutated HLA-A2 Molecule is Recognized by RCCospecific CTL Clone 314/4. The finding that the product of cDNA 3B10 alone was recognized by CTL 314/4 (Fig. 2) , and the capacity ofanti-HLA-A2 mAbs to block the recognition ofLB996-P, CC cells by CTL 314/4 ( Fig. 1 B) indicated that cDNA 3B10 itself might code for a HLA-A2 molecule. In fact, the sequence of cDNA 3B10 proved identical to that of HLA-A*0201 with the exception of one was replaced by a thymine (T), which resulted in an arginine (R) to isoleucine (I) exchange at residue 170 (Fig.3 A) . Accordingly, the amino acid replacement was referred to as R170I, and the HLA-A2 gene expressed by LB996-RCC cells was named HLA-A*O201-R170I. As shown in Fig. 4 , residue 170 is located on the o~-helix of the r domain.
This new HLA-A2 sequence did not correspond to a previously described HLA-A2 allele. Therefore, to determine whether HLA-A*0201-tL170I represented a new HLA-A2 allele, or resulted from a somatic point mutation in tumor LB996-RCC, we analyzed the corresponding sequence in normal cells from the same patient. We amplified by R.T-PCtL the coding region of the HLA-A2 gene expressed by PBL LB996-PBL, and cloned it into expression vector pcDNA3. This HLA-A2 sequence proved identical to that of HLA-A*0201, thus differing from the HLA-A*O201-R170I sequence by one nucleotide (Fig. 3, A and   B ). Since patient LB996 was HLA-typed A2 and All, the two HLA-A2 sequences could not represent two alleles of the HLA-A2 locus. We concluded that the R170I replacement was created by a somatic mutation in the tumor cells.
To confirm the role of this mutation in creating the antigen recognized by CTL 314/4, we transfected COS-7 cells (Fig. 5 B) .
Autologous EBV-transformed B cells pulsed with different peptides derived from the mutant region of HLA-A*0201-tL170I were not recognized by CTL 314/4, suggesting that the CTL recognizes the altered HLA-A2 molecule itself rather than a mutant peptide presented by autologous MHC molecules (data not shown).
The R 1701 Mutation Occurred In Vivo. T o d e t e r m i n e w h e t h e r the R 1 7 0 I m u t a t i o n was already present in the original t u m o r tissue or w h e t h e r it was g e n e r a t e d in vitro in
L B 9 9 6 -R C C cells, we designed specific primers to selectively amplify by P C R either the n o r m a l H L A -A * 0 2 0 I or the m u t a t e d sequence. W h e r e a s L B 9 9 6 -P B L a n d the cultured L B 9 9 6 -R C C cell line only c o n t a i n e d the w i l d -t y p e or the m u t a t e d s e q u e n c e respectively, b o t h sequences were f o u n d in the initial t u m o r tissue (Fig. 6 ), T h e w e a k signal for the w i l d -t y p e gene is probably d u e to some n o r m a l cells that were surgically r e m o v e d t o g e t h e r with the t u m o r 1-6) or HLA-A*0201 (lanes 7-12) . RNA integrity was checked by RT and amplification of 13-actin mlKNA (lanes [13] [14] [15] [16] . Control templates included plasmid pcDNA3 (25 pg) containing cDNA HLA-A*O201-R1701 or HLA-A*0201. ical origins were screened by R T -P C R . All samples proved negative for the mutated sequence (data not shown).
Recognition of the Mutated HLA-A*0201 Molecule by mAbs.
To examine the influence o f the R170I mutation on the structure o f the HLA-A*0201 molecule, a panel o f HLA-A2-specific mAbs was used to detect altered antibody binding sites by flow cytometry. Whereas mAbs C1Lll-351, BB7.2, and PA2.1 stained lymphocytes o f patient LB996 with the same intensity as the R C C fine, the binding of mAb MA2.1 was strongly reduced on L B 9 9 6 -R C C cells when compared with autologous lymphocytes (Fig. 7) . Although the binding site o f m A b MA2.1 has previously been mapped to residues 62-66 on the a-helix o f the e~l domain (35) , the finding that residue 170, which is located on the a-helix of the or2 domain, also affects binding ofMA2.1, is in agreement with a previous report (36) , and suggests that the epitope is not limited to the oil helix (Fig. 4) .
Discussion
The ability o f point mutations to generate new antigens recognized by T cells was first demonstrated by the analysis of turn-antigens, which appear on mouse tumor cells after in vitro mutagenesis (37) . These mutations occur in genes expressed ubiquitously, and the resulting amino acid substitutions generate new antigenic peptides, either by creating an agretope enabling the mutated peptide to bind to M H C molecules, or by creating a new epitope in a peptide already able to bind (38) . This mechanism was later found to be responsible for the presence o f T cell antigens on both murine and human tumors, in the absence of any in vitro mutagenesis (12, 13, 39, 40) . So far, all tumor antigens generated by point mutations correspond to mutated peptides presented by M H C molecules.
The antigen described here also results from a tumor- specific point mutation. However, this mutation does not create a new antigenic peptide, but rather modifies the structure of the HLA-A2 molecule which now appears to be recognized per se. The ability o f altered M H C molecules to act as tumor-specific antigens has been extensively debated, starting with observations by Invernizzi and Parmiani (41, 42) . The mutated HLA-A2 molecule described here is the first instance of a somatic point mutation changing an amino acid in a M H C class I molecule, thereby transforming it into a target structure that is recognized by autologous CTL. Because this mutation is present in tumor cells and not in autologous normal cells, the antigen is strictly tumor specific and therefore represents an ideal target for cancer immunotherapy. O n the other hand, since the mutation, and consequently the antigen, are unique to an individual tumor, no vaccine of general use can be based on it. The structural basis for recognition o f the altered HLA-A2 molecule by the TCR is not clear: either the mutant HLA-A2 binds a different set of endogenous peptides, one of which is recognized by the receptor, or the receptor interacts directly with the altered HLA-A2 molecule independently of a specific peptide. Preliminary experiments suggest that acid elution of peptides bound to HLA molecules of LB996-RCC cells does not affect recognition by CTL 314/4, whereas recognition by a control CTL was reduced (data not shown). This observation would tend to favor the last hypothesis. This antigen appears to be strongly immunogenic in vitro, since all 25 LB996-RCC-specific CTL clones that were isolated recognized HLA-A*0201-R170I (data not shown). Since patier!t LB996 did not reject his tumor, one might ask why he failed to mount an effective antitumor immune response in vivo. There are several possible explanations of the paradox of in vitro measurable CTL reactivity without tumor response in vivo. First, tumor-specific T cells might be present in vivo but unresponsive. This might be due to the absence on tumor cells of costimulatory molecules required for efficient stimulation of T cells (for a review see reference 43). T cells infiltrating kidney tumors were shown to express reduced levels of the TCR ~ chain, which might partly explain the unresponsiveness resulting from incomplete stimulation with tumor antigens (44, 45) . Such T cells could, however, respond in vitro in the presence of lymphokines replacing the missing costimulatory signal. The finding that costimulation of CD8 + T cells by B7-transfected melanoma cells resulted in tumor rejection in two mouse models supports the importance of providing two signals to T lymphocytes (46, 47) . Another reason for the absence of an effective antitumor response in vivo could be the selective deletion of tumor-specific high-avidity T cells due to the presence of the tumor. Similar to observations in spleen-chimeric mice (48) , and in H-2 transgenic mice (49), it is possible that the remaining low-avidity T cells lack potent functional activity in vivo, but can respond in vitro under appropriate stimulatory conditions, leading to a state of split tolerance.
Regardless of the mechanism underlying the unresponsiveness in vivo, it may be possible to immunize patients against mutated antigens by using presentation by dendritic cells, or by injecting the antigen together with adjuvants or lymphokines. Although unique antigens are restricted to individual tumors, their exquisite tumor specificity would make them very safe targets for such active immunizations. In addition, transplantation studies with chemically induced mouse tumors have shown that unique antigens can be very strong immunogenic rejection antigens (38, 50) . The observation that tumor cells are frequently deficient in DNA-repairing enzymes (51) (52) (53) (54) (55) , and therefore accumulate mutations possibly generating new antigenic peptides, suggests that such unique antigens may be frequently present on human tumors. It is not impossible that future technical improvements will allow the design of individually specific vaccines based on defined unique antigens.
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